Evidence map›Paper›PMID 25436773›Full record

ArticlePloS one2014

Silica nanoparticles as the adjuvant for the immunisation of mice using hepatitis B core virus-like particles.

Dace Skrastina, Ivars Petrovskis, Ilva Lieknina, Janis Bogans, Regina Renhofa, Velta Ose, Andris Dishlers, Yuri Dekhtyar, Paul Pumpens

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 57 citations in OpenAlex.

  1. Review
  2. Article
  3. Strategies for safe management of hospital wastewater during the COVID-19 pandemic.International journal of environmental science and technology : IJEST · 2023
    Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Ultrasmall silica nanoparticles directly ligate the T cell receptor complex.Proceedings of the National Academy of Sciences of the United States of America · 2020
    Article
  9. Article
  10. Article
  11. Nano-based approach to combat emerging viral (NIPAH virus) infection.Nanomedicine : nanotechnology, biology, and medicine · 2019
    Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Dace SkrastinaLatvian Biomedical Research and Study Centre, Riga, Latvia.
Ivars PetrovskisLatvian Biomedical Research and Study Centre, Riga, Latvia.
Ilva LiekninaLatvian Biomedical Research and Study Centre, Riga, Latvia.
Janis BogansLatvian Biomedical Research and Study Centre, Riga, Latvia.
Regina RenhofaLatvian Biomedical Research and Study Centre, Riga, Latvia.
Velta OseLatvian Biomedical Research and Study Centre, Riga, Latvia.
Andris DishlersLatvian Biomedical Research and Study Centre, Riga, Latvia.
Yuri DekhtyarInstitute of Biomedical Engineering and Nanotechnologies, Riga Technical University, Riga, Latvia.
Paul PumpensLatvian Biomedical Research and Study Centre, Riga, Latvia.
Latvian Biomedical Research and Study Centre · LVRiga Technical University · LV

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Advances in nanotechnology and nanomaterials have facilitated the development of silicon dioxide, or Silica, particles as a promising immunological adjuvant for the generation of novel prophylactic and therapeutic vaccines. In the present study, we have compared the adjuvanting potential of commercially available Silica nanoparticles (initial particles size of 10-20 nm) with that of aluminium hydroxide, or Alum, as well as that of complete and incomplete Freund's adjuvants for the immunisation of BALB/c mice with virus-like particles (VLPs) formed by recombinant full-length Hepatitis B virus core (HBc) protein. The induction of B-cell and T-cell responses was studied after immunisation. Silica nanoparticles were able to adsorb maximally 40% of the added HBc, whereas the adsorption capacity of Alum exceeded 90% at the same VLPs/adjuvant ratio. Both Silica and Alum formed large complexes with HBc VLPs that sedimented rapidly after formulation, as detected by dynamic light scattering, spectrophotometry, and electron microscopy. Both Silica and Alum augmented the humoral response against HBc VLPs to the high anti-HBc level in the case of intraperitoneal immunisation, whereas in subcutaneous immunisation, the Silica-adjuvanted anti-HBc level even exceeded the level adjuvanted by Alum. The adjuvanting of HBc VLPs by Silica resulted in the same typical IgG2a/IgG1 ratios as in the case of the adjuvanting by Alum. The combination of Silica with monophosphoryl lipid A (MPL) led to the same enhancement of the HBc-specific T-cell induction as in the case of the Alum and MPL combination. These findings demonstrate that Silica is not a weaker putative adjuvant than Alum for induction of B-cell and T-cell responses against recombinant HBc VLPs. This finding may have an essential impact on the development of the set of Silica-adjuvanted vaccines based on a long list of HBc-derived virus-like particles as the biological component.

Indexed as

Adjuvants, ImmunologicAlum CompoundsAnimalsFemaleFreund's AdjuvantHepatitis BHepatitis B Core AntigensHepatitis B VaccinesHepatitis B virusImmunity, HumoralImmunizationLipid ALipidsMice, Inbred BALB CNanoparticlesSilicon DioxideAdjuvants, ImmunologicAlum Compoundsaluminum sulfateFreund's AdjuvantHepatitis B Core AntigensHepatitis B Vaccinesincomplete Freund's adjuvantLipid ALipidsmonophosphoryl lipid ASilicon Dioxide

Identifiers

PMID25436773
PMCPMC4250084
OpenAlexW1977193733

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.